Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.55 |
| ▸ | MTOR | P42345 | 13/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.35 |
| ▸ | PDE4A | P27815 | 6/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026400 | 0.92 | PIK3CA (0.54) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL11030367 | 0.91 | PIK3CA (0.53) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL11028351 | 0.89 | PIK3CA (0.54) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL11031161 | 0.89 | PIK3CA (0.59) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL2788184 | 0.87 | PIK3CA (0.61) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL16161697 | 0.87 | PIK3CA (0.61) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL16161706 | 0.86 | PIK3CA (0.57) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL11031084 | 0.85 | PIK3CA (0.59) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL11030961 | 0.84 | PIK3CA (0.58) | PIK3CAMTORPDE4BPDE4DPDE4A | |
| SCHEMBL750793 | 0.84 | PIK3CA (0.58) | PIK3CAMTORPDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885PDE4B 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.